Chief Executive Officer
Mr. Joel Tune currently serves as Enteris BioPharma’s Executive Chairman of the Board of Directors and Chief Executive Officer. He joined the Company in July 2013, initially serving as the Executive Chairman of the Board of Directors. In January 2016, Mr. Tune assumed the role of Chief Executive Officer of Enteris BioPharma. Joel is a highly seasoned executive with an extensive knowledge of strategy, operations and business development.
Prior to joining Enteris BioPharma, Mr. Tune spent 28 years with Baxter HealthCare Corp. in roles of increasing responsibility within product development, sales and marketing, strategy, mergers and acquisitions and general management. His last role at Baxter was as Vice President and General Manager of the BioPharma Solutions Business, with global responsibility for the rapidly growing $800M franchise. Since leaving Baxter he has served as an independent consultant to a variety of private equity, venture capital and healthcare start-up firms, including serving on the Board of Directors for Unigene Laboratories and Epic Therapeutics. Mr. Tune holds an MBA from Marquette University and a BS in Biomedical Engineering from University of Louisville.
President, Chief Financial Officer
Mr. Brian Zietsman currently serves as Enteris BioPharma's President and Chief Financial Officer having joined the Company in July 2013. He brings more than 20 years of strategic finance and accounting experience to his position, over half of which has been in the pharmaceutical industry for both public and private companies.
Prior to joining Enteris BioPharma, Mr. Zietsman was the Chief Financial Officer of Unigene Laboratories, Inc. where he played a pivotal role in that company’s restructuring. Prior to working at Unigene, he was the Corporate Controller at Duff & Phelps (NYSE DUF) and between 2005 and 2011, he worked in various financial capacities at Enzon Pharmaceuticals, Inc., (Nasdaq: ENZN), including Vice President and Corporate Controller. Prior to Enzon, Mr. Zietsman was the Corporate Controller at Reliant Pharmaceuticals, Inc., a privately held company which was acquired by GlaxoSmithKline, and earlier worked at Deloitte where he held various positions of increasing responsibility, leaving as a Senior Manager in the audit group.
Mr. Zietsman is a graduate from Rhodes University, South Africa where he earned his B. Com (Accounting), BSc (Computer Science) and HDIPACC certifications. Mr. Zietsman is a registered CPA.
Paul Shields, Ph.D.
Chief Operating Officer
Dr. Paul Shields is Enteris BioPharma's Chief Operating Officer. He joined the Company in July 2013, initially serving as the Company's Vice President, Operations. He brings more than 24 years of experience in the biopharmaceutical industry, focusing on Chemistry, Manufacturing and Controls (CMC) for a variety of products.
Dr. Shields previously served as the Vice President, Manufacturing Operations for Unigene Laboratories from 2005 to 2013, where he managed commercial CMC operations for recombinant active ingredients, and clinical and commercial supplies of nasal spray and solid dose products. Prior to that, he served as Unigene’s Director of Plant Operations from 2001 through 2005, as Plant Manager from 1995 through 2001, and in various other capacities with Unigene from 1989 through 1995.
Dr. Shields holds a Ph.D. in biochemistry from the University of Pennsylvania and a B.S. in chemical engineering from the University of Michigan.
Gary A. Shangold, M.D.
Chief Medical Officer
Dr. Shangold is Enteris BioPharma’s Chief Medical Officer, joining the Company in January 2020. He brings more than 25 years of pharmaceutical industry and consulting experience in clinical research and regulatory affairs.
Dr. Shangold is a seasoned industry professional having held C-suite level roles at a variety of innovative organizations. Prior to joining Enteris BioPharma, Dr. Shangold was the founder and CEO of InteguRx Therapeutics, a company developing transdermal pharmaceutical products. He was formerly Chief Medical Officer / Executive VP for R&D at Xanodyne Pharmaceuticals. Before that, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company. Earlier still, he worked at Johnson & Johnson Pharmaceutical R&D, where he held several senior roles in Clinical Research and Regulatory Affairs. Prior to J&J, Dr. Shangold was Medical Director of Ob/Gyn/Infertility at Serono Labs.
Before his 25 years in industry, Dr. Shangold spent a decade in academia, on the faculty of The University of Chicago Pritzker School of Medicine, and then later at Massachusetts General Hospital and the Harvard School of Medicine.
Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / University of Miami and a fellowship in Reproductive Endocrinology at the L.A. County / University of Southern California Medical Center. He received a BA in Social Behavior from the University of Pennsylvania, and an MD from the Columbia University College of Physicians and Surgeons.